



GNF 23 R1C23

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicant : Eaton, et al.  
Appl. No. : 10/063,534  
Filed : May 2, 2002  
For : ANTIBODIES TO A  
POLYPEPTIDE ENCODED BY A  
NUCLEIC ACID  
OVEREXPRESSED IN KIDNEY  
TUMOR AND  
UNDEREXPRESSED IN LUNG  
TUMOR (as amended)  
Examiner : Seharaseyon, J.  
Group Art Unit : 1647

CERTIFICATE OF MAILING

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

September 2, 2004

(Date)

  
AnneMarie Kaiser, Reg. No. 37,649

RESPONSE TO NOTICE TO COMPLY

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

This Response to the Notice to Comply conforms the Sequence Listing to the rules of practice specified by the United States Patent and Trademark Office. Submitted herewith is a paper copy of the Sequence Listing and a copy of the Notice to Comply.

Please enter the attached sequence listing in the above-referenced application.

VERIFICATION UNDER 37 C.F.R. §1.821(f) & (g)

The sequences appearing in the attached Sequence Listing were included in the application as filed. Pursuant to 37 C.F.R. §1.821(g), no new matter is being added herewith. As required under 37 C.F.R. §1.821(f), I hereby verify that the data on the disk previously submitted and the paper copy of the Sequence Listing are identical.

Appl. No. : 10/063,534  
Filed : May 2, 2002

Applicants believe this response to Notice to Comply brings the present application into compliance with the Sequence Listing requirements. A copy of the Notice to Comply is also submitted herewith.


Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP


Dated: Sept. 2, 2004

By:

  
AnneMarie Kaiser  
Registration No. 37,649  
Attorney of Record  
Customer No. 30,313  
(619) 235-8550

S:\DOCS\BSG\BSG-1357.DOC  
081304

**COPY**



<b>Notice to Comply</b>	Application No. <b>10/063 534</b>	Applicant(s) <b>EATON ET AL</b>
	Examiner <b>J. Schrareyam</b>	Art Unit <b>1647</b>
<b>NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES</b>		
<p>Applicant must file the items indicated below within the time period set the Office action to which the Notice is attached to avoid abandonment under 35 U.S.C. § 133 (extensions of time may be obtained under the provisions of 37 CFR 1.136(a)).</p> <p>The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):</p> <p><input type="checkbox"/> 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998).</p> <p><input checked="" type="checkbox"/> 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).</p> <p><input type="checkbox"/> 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).</p> <p><input type="checkbox"/> 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."</p> <p><input type="checkbox"/> 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).</p> <p><input type="checkbox"/> 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).</p> <p><input type="checkbox"/> 7. Other:</p> <p><b>Applicant Must Provide:</b></p> <p><input type="checkbox"/> An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".</p> <p><input checked="" type="checkbox"/> An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.</p> <p><input checked="" type="checkbox"/> A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).</p> <p>For questions regarding compliance to these requirements, please contact:</p> <p>For Rules Interpretation, call (703) 308-4216 or (703) 308-2923</p> <p>For CRF Submission Help, call (703) 308-4212 or 308-2923</p> <p>PatentIn Software Program Support</p> <p>Technical Assistance.....703-287-0200</p> <p>To Purchase PatentIn Software.....703-306-2600</p>		

GenBank (Release 142, jun 2004)

494 100 0.0  
 P\_AAF92072 Human PRO831 cDNA. 494 bp, cDNA, PAT 15-MAY-2001  
 ACCESSION P\_AAF92072  
 KEYWORDS GENSEQ; Human; PRO protein; mapping; patent; patentdb (v200414,  
 01-JUL-2004).  
 SOURCE Homo sapiens.  
 ORGANISM Homo sapiens.  
 REFERENCE 1 (bases 1 to 494)  
 AUTHORS Eaton,D.L., Filvaroff,E., Gerritsen,M.E., Goddard,A.,  
 Godowski,P.J. Grimaldi,C.J., Gurney,A.L., Watanabe,C.K.,  
 Wood,W.I.  
 TITLE Eighty four nucleic acids encoding PRO polypeptides, useful in  
 molecular biology, including use as hybridization probes, and in  
 chromosome and gene mapping.  
 JOURNAL Patent: WO200116318-A2; Filing Date: 24-AUG-2000; 2000WO-US023328;  
 Publication Date: 08-MAR-2001; Priority: 01-SEP-1999;  
 99WO-US020111. 15-SEP-1999; 99WO-US021090. 07-DEC-1999;  
 99US-0169495P. 09-DEC-1999; 99US-0170262P. 11-JAN-2000;  
 2000US-0175481P. 18-FEB-2000; 2000WO-US004341. 18-FEB-2000;  
 2000WO-US004342. 22-FEB-2000; 2000WO-US004414. 01-MAR-2000;  
 2000WO-US005601. 03-MAR-2000; 2000US-0187202P. 21-MAR-2000;  
 2000US-0191007P. 30-MAR-2000; 2000WO-US008439. 25-APR-2000;  
 2000US-0199397P. 22-MAY-2000; 2000WO-US014042. 05-JUN-2000;  
 2000US-0209832P; Assignee: (GETH ) GENENTECH INC; Cross Reference:  
 WPI; 2001-183260/18. P-PSDB; AAB87540; Patent Format: Claim 2; Fig  
 29; 278pp; English.

COMMENT The present sequence is the coding sequence for a human PRO  
 polypeptide (secreted and transmembrane). The PRO protein, and PRO  
 agonists, PRO antagonists or anti-PRO antibodies are useful for  
 preparation of a medicament useful in the treatment of a condition  
 which is responsive to the PRO protein, agonists, antagonists or  
 anti-PRO antibodies. The PRO protein may also be employed as  
 molecular weight markers for protein electrophoresis. The PRO  
 coding sequence has applications in molecular biology, including  
 use as hybridisation probes, and in chromosome and gene mapping

FEATURES Location/Qualifiers  
 BASE COUNT 128 a 111 c 120 g 135 t  
 ORIGIN

494 100 0.0  
 AX092298 Sequence 29 from Patent WO0116318. 494 bp,  
 DNA, linear, PAT 21-MAR-2001  
 ACCESSION AX092298  
 VERSION AX092298.1 GI:13444463  
 KEYWORDS  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1  
 AUTHORS Eaton,D.L., Filvaroff,E., Gerritsen,M.E., Goddard,A.,  
 Godowski,P.J., Grimaldi,C.J., Gurney,A.L., Watanabe,C.K. and  
 Wood,W.I.  
 TITLE Secreted and transmembrane polypeptides and nucleic acids encoding  
 the same

JOURNAL Patent: WO 0116318-A 29 08-MAR-2001;  
 Genentech, Inc. (US)

FEATURES Location/Qualifiers  
 source 1..494  
 /organism="Homo sapiens"  
 /mol\_type="unassigned DNA"  
 /db\_xref="taxon:9606"

BASE COUNT  
 ORIGIN

493 100 0.0

P\_AAA37028 Human PRO831 (UNQ471) cDNA sequence SEQ ID NO:21. 493 bp,  
 cDNA, PAT 08-AUG-2000

ACCESSION P\_AAA37028

KEYWORDS GENESEQ; Human; PRO polypeptide; membrane bound protein; receptor;  
 diagnosis; transmembrane; secretion; immunoadhesion; pharmaceutical;  
 screening; patent; patentdb (v200414, 01-JUL-2004).

SOURCE Homo sapiens.

ORGANISM Homo sapiens.

REFERENCE 1 (bases 1 to 493)

AUTHORS Baker,K., Goddard,A., Gurney,A.L., Smith,V., Watanabe,C.K.,  
 Wood,W.I.

TITLE New mammalian DNA sequences encoding transmembrane, receptor or  
 secreted PRO polypeptides, useful for screening of potential  
 peptide or small molecule inhibitors of the relevant  
 receptor/ligand interactions.

JOURNAL Patent: WO200012708-A2; Filing Date: 01-SEP-1999; 99WO-US020111;  
 Publication Date: 09-MAR-2000; Priority: 01-SEP-1998;  
 98US-0098716P. 01-SEP-1998; 98US-0098749P. 01-SEP-1998;  
 98US-0098750P. 02-SEP-1998; 98US-0098803P. 02-SEP-1998;  
 98US-0098821P. 02-SEP-1998; 98US-0098843P. 09-SEP-1998;  
 98US-0099536P. 09-SEP-1998; 98US-0099596P. 09-SEP-1998;  
 98US-0099598P. 09-SEP-1998; 98US-0099602P. 09-SEP-1998;  
 98US-0099642P. 10-SEP-1998; 98US-0099741P. 10-SEP-1998;  
 98US-0099754P. 10-SEP-1998; 98US-0099763P. 10-SEP-1998;  
 98US-0099792P. 10-SEP-1998; 98US-0099808P. 10-SEP-1998;  
 98US-0099812P. 10-SEP-1998; 98US-0099815P. 10-SEP-1998;  
 98US-0099816P. 15-SEP-1998; 98US-0100385P. 15-SEP-1998;  
 98US-0100388P. 15-SEP-1998; 98US-0100390P. 16-SEP-1998;  
 98US-0100584P. 16-SEP-1998; 98US-0100627P. 16-SEP-1998;  
 98US-0100661P. 16-SEP-1998; 98US-0100662P. 16-SEP-1998;  
 98US-0100664P. 17-SEP-1998; 98US-0100683P. 17-SEP-1998;  
 98US-0100684P. 17-SEP-1998; 98US-0100710P. 17-SEP-1998;  
 98US-0100711P. 17-SEP-1998; 98US-0100919P. 17-SEP-1998;  
 98US-0100930P. 18-SEP-1998; 98US-0100848P. 18-SEP-1998;  
 98US-0100849P. 18-SEP-1998; 98US-0101014P. 18-SEP-1998;  
 98US-0101068P. 18-SEP-1998; 98US-0101071P. 22-SEP-1998;  
 98US-0101279P. 23-SEP-1998; 98US-0101471P. 23-SEP-1998;  
 98US-0101472P. 23-SEP-1998; 98US-0101474P. 23-SEP-1998;  
 98US-0101475P. 23-SEP-1998; 98US-0101476P. 23-SEP-1998;  
 98US-0101477P. 23-SEP-1998; 98US-0101479P. 24-SEP-1998;  
 98US-0101738P. 24-SEP-1998; 98US-0101741P. 24-SEP-1998;  
 98US-0101743P. 24-SEP-1998; 98US-0101915P. 24-SEP-1998;  
 98US-0101916P. 29-SEP-1998; 98US-0102207P. 29-SEP-1998;  
 98US-0102240P. 29-SEP-1998; 98US-0102307P. 29-SEP-1998;  
 98US-0102330P. 29-SEP-1998; 98US-0102331P. 30-SEP-1998;  
 98US-0102484P. 30-SEP-1998; 98US-0102487P. 30-SEP-1998;

98US-0102570P. 30-SEP-1998; 98US-0102571P. 01-OCT-1998;  
 98US-0102684P. 01-OCT-1998; 98US-0102687P. 02-OCT-1998;  
 98US-0102965P. 06-OCT-1998; 98US-0103258P. 06-OCT-1998;  
 98US-0103449P. 07-OCT-1998; 98US-0103314P. 07-OCT-1998;  
 98US-0103315P. 07-OCT-1998; 98US-0103328P. 07-OCT-1998;  
 98US-0103395P. 07-OCT-1998; 98US-0103396P. 07-OCT-1998;  
 98US-0103401P. 08-OCT-1998; 98US-0103633P. 08-OCT-1998;  
 98US-0103678P. 08-OCT-1998; 98US-0103679P. 08-OCT-1998;  
 98US-0103711P. 14-OCT-1998; 98US-0104257P. 20-OCT-1998;  
 98US-0104987P. 20-OCT-1998; 98US-0105000P. 20-OCT-1998;  
 98US-0105002P. 21-OCT-1998; 98US-0105104P. 22-OCT-1998;  
 98US-0105169P. 22-OCT-1998; 98US-0105266P. 26-OCT-1998;  
 98US-0105693P. 26-OCT-1998; 98US-0105694P. 27-OCT-1998;  
 98US-0105807P. 27-OCT-1998; 98US-0105881P. 27-OCT-1998;  
 98US-0105882P. 27-OCT-1998; 98US-0106062P. 28-OCT-1998;  
 98US-0106023P. 28-OCT-1998; 98US-0106029P. 28-OCT-1998;  
 98US-0106030P. 28-OCT-1998; 98US-0106032P. 28-OCT-1998;  
 98US-0106033P. 28-OCT-1998; 98US-0106178P. 29-OCT-1998;  
 98US-0106248P. 29-OCT-1998; 98US-0106384P. 29-OCT-1998;  
 98US-0108500P. 30-OCT-1998; 98US-0106464P. 03-NOV-1998;  
 98US-0106856P. 03-NOV-1998; 98US-0106902P. 03-NOV-1998;  
 98US-0106905P. 03-NOV-1998; 98US-0106919P. 03-NOV-1998;  
 98US-0106932P. 03-NOV-1998; 98US-0106934P. 10-NOV-1998;  
 98US-0107783P. 17-NOV-1998; 98US-0108775P. 17-NOV-1998;  
 98US-0108779P. 17-NOV-1998; 98US-0108787P. 17-NOV-1998;  
 98US-0108788P. 17-NOV-1998; 98US-0108801P. 17-NOV-1998;  
 98US-0108802P. 17-NOV-1998; 98US-0108806P. 17-NOV-1998;  
 98US-0108807P. 17-NOV-1998; 98US-0108867P. 17-NOV-1998;  
 98US-0108925P. 18-NOV-1998; 98US-0108848P. 18-NOV-1998;  
 98US-0108849P. 18-NOV-1998; 98US-0108850P. 18-NOV-1998;  
 98US-0108851P. 18-NOV-1998; 98US-0108852P. 18-NOV-1998;  
 98US-0108858P. 18-NOV-1998; 98US-0108904P; Assignee: (GETH )  
 GENENTECH INC; Cross Reference: WPI; 2000-237871/20. P-PSDB;  
 AAY99346; Patent Format: Claim 2; Fig 13; 773pp; English.

**COMMENT** AAA37022 to AAA37144 encode the new isolated human transmembrane, receptor or secreted PRO polypeptides given in AAY99340 to AAY99462. The transmembrane and receptor PRO proteins can be used for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interactions. The polypeptides and nucleotide sequences encoding them have various industrial applications, including uses as pharmaceutical and diagnostic agents. AAA37145 to AAA37330 represent PCR primers and hybridisation probes used in the isolation of the PRO polypeptides from the present invention

**FEATURES** Location/Qualifiers  
**BASE COUNT** 127 a 111 c 120 g 135 t  
**ORIGIN**

486 100 0.0  
 BC021104 Homo sapiens apelin, AGTRL1 ligand, mRNA (cDNA clone MGC:31846 IMAGE:4586949), complete cds. 2673 bp, mRNA, linear, PRI 30-JUN-2004

**ACCESSION** BC021104  
**VERSION** BC021104.1 GI:18088893  
**KEYWORDS** MGC.  
**SOURCE** Homo sapiens (human)  
**ORGANISM** Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;  
 Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

**REFERENCE** 1 (bases 1 to 2673)  
**AUTHORS** Strausberg, R.L., Feingold, E.A., Grouse, L.H., Derge, J.G., Klausner, R.D., Collins, F.S., Wagner, L., Shenmen, C.M., Schuler, G.D., Altschul, S.F., Zeeberg, B., Buetow, K.H., Schaefer, C.F., Bhat, N.K., Hopkins, R.F., Jordan, H., Moore, T., Max, S.I., Wang, J., Hsieh, F., Diatchenko, L., Marusina, K., Farmer, A.A., Rubin, G.M., Hong, L., Stapleton, M., Soares, M.B., Bonaldo, M.F., Casavant, T.L., Scheetz, T.E., Brownstein, M.J., Usdin, T.B., Toshiyuki, S., Carninci, P., Prange, C., Raha, S.S., Loquellano, N.A., Peters, G.J., Abramson, R.D., Mullahy, S.J., Bosak, S.A., McEwan, P.J., McKernan, K.J., Malek, J.A., Gunaratne, P.H., Richards, S., Worley, K.C., Hale, S., Garcia, A.M., Gay, L.J., Hulyk, S.W., Villalon, D.K., Muzny, D.M., Sodergren, E.J., Lu, X., Gibbs, R.A., Fahey, J., Helton, E., Ketteman, M., Madan, A., Rodrigues, S., Sanchez, A., Whiting, M., Madan, A., Young, A.C., Shevchenko, Y., Bouffard, G.G., Blakesley, R.W., Touchman, J.W., Green, E.D., Dickson, M.C., Rodriguez, A.C., Grimwood, J., Schmutz, J., Myers, R.M., Butterfield, Y.S., Krzywinski, M.I., Skalska, U., Smailus, D.E., Schnerch, A., Schein, J.E., Jones, S.J. and Marra, M.A.

**TITLE** Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences  
**JOURNAL** Proc. Natl. Acad. Sci. U.S.A. 99 (26), 16899-16903 (2002)  
**REFERENCE** 2 (bases 1 to 2673)  
**AUTHORS** Strausberg, R.  
**TITLE** Direct Submission  
**JOURNAL** Submitted (03-JAN-2002) National Institutes of Health, Mammalian Gene Collection (MGC), Cancer Genomics Office, National Cancer Institute, 31 Center Drive, Room 11A03, Bethesda, MD 20892-2590, USA  
**REMARK** NIH-MGC Project URL: <http://mgc.nci.nih.gov>  
**COMMENT** Contact: MGC help desk  
 Email: [cgapbs-r@mail.nih.gov](mailto:cgapbs-r@mail.nih.gov)  
 Tissue Procurement: DCTD/DTP  
 cDNA Library Preparation: Rubin Laboratory  
 cDNA Library Arrayed by: The I.M.A.G.E. Consortium (LLNL)  
 DNA Sequencing by: Genome Sequence Centre,  
 BC Cancer Agency, Vancouver, BC, Canada  
[info@bcgsc.bc.ca](mailto:info@bcgsc.bc.ca)  
 Steve Jones, Sarah Barber, Mabel Brown-John, Yaron Butterfield, Andy Chan, Steve S. Chand, William Chow, Alison Cloutier, Ruth Featherstone, Malachi Griffith, Obi Griffith, Ran Guin, Nancy Liao, Kim MacDonald, Amara Masson, Mike R. Mayo, Josh Moran, Ryan Morin, Teika Olson, Diana Palmquist, Anca Petrescu, Anna Liisa Prahbu, Parvaneh Saeedi, JR Santos, Angelique Schnerch, Ursula Skalska, Duane Smailus, Jeff Stott, Miranda Tsai, George Yang, Jacquie Schein, Asim Siddiqui, Rob Holt, Marco Marra.  
 Clone distribution: MGC clone distribution information can be found through the I.M.A.G.E. Consortium/LLNL at: <http://image.llnl.gov>  
 Series: IRAL Plate: 40 Row: f Column: 18  
 This clone was selected for full length sequencing because it passed the following selection criteria: matched mRNA gi: 21314667.

**FEATURES** Location/Qualifiers  
 source 1..2673  
 /organism="Homo sapiens"

```

/mol_type="mRNA"
/db_xref="taxon:9606"
/clone="MGC:31846 IMAGE:4586949"
/tissue_type="Kidney, renal cell adenocarcinoma"
/clone_lib="NIH_MGC_14"
/lab_host="DH10B-R"
/note="Vector: pOTB7"

gene 1..2673
/gene="APLN"
/note="synonyms: XNPEP2, apelin"
/db_xref="LocusID:8862"
/db_xref="MIM:300297"

CDS 308..541
/gene="APLN"
/codon_start=1
/product="apelin, preproprotein"
/protein_id="AAH21104.2"
/db_xref="GI:45946592"
/db_xref="LocusID:8862"
/db_xref="MIM:300297"

```

BASE COUNT

ORIGIN

468 100 0.0

P\_AAX235184 Human kidney aminopeptidase P genomic DNA fragment 2. 998 bp,  
DNA, PAT 23-JUN-1999

ACCESSION P\_AAX23518

KEYWORDS GENESEQ; Aminopeptidase; human; AmP; gene therapy; treatment;  
AmP-deficiency; prenatal diagnosis; angioedema; antihypertensive  
agent; atherosclerosis; arterial stenosis; industrial protein feed;  
malabsorption syndrome; proteinaceous waste degradation; additive;  
immunohistochemistry; patent; patentdb (v200414, 01-JUL-2004).

SOURCE Homo sapiens.

ORGANISM Homo sapiens.

REFERENCE 1 (bases 1 to 49998)

AUTHORS Ryan, J.W., Sprinkle, T.J.C., Venema, R.C.

TITLE Nucleic acid encoding human aminopeptidase P.

JOURNAL Patent: WO9911799-A2; Filing Date: 02-SEP-1998; 98WO-US018426;  
Publication Date: 11-MAR-1999; Priority: 02-SEP-1997;  
97US-0057854P; Assignee: (MEDI-) MEDICAL COLLEGE GEORGIA RES INST;  
Cross Reference: WPI; 1999-205193/17; Patent Format: Claim 13; Page  
109-139; 201pp; English.COMMENT This invention describes the isolation of a novel human  
aminopeptidase P (AmP). This protein is used to produce recombinant  
AmP and can be used for gene therapy for treating AmP-deficiency  
conditions. Its fragments are used as primers and probes to  
identify patients with homozygous and heterozygous AmP deficiency,  
including prenatal diagnosis (patients defective in AmP are at risk  
of developing angioedema if treated with angiotensin-converting  
enzyme inhibitors), also as antisense inhibitors in cases of  
excessive AmP expression. The product of the invention is also used  
to identify AmP-expressing sequences in other animals and to  
generate transgenic animals, and comparisons of genomic sequences  
are used to detect mutations. AmP inhibitors are potentially useful  
as antihypertensive agents and to prevent or treat arterial  
(re)stenosis or atherosclerosis. The structure of AmP is used to  
design synthetic substrates, e.g. for use in AmP assays. AmP, which

hydrolyzes N-terminal imido bonds, can be used to degrade industrial protein feeds to free amino acids, to degrade proteinaceous wastes, as additives in enzyme formulations used to treat malabsorption syndrome and for studying its biological role. Antibodies against AmP are used in immunohistochemical methods to study AmP distribution

FEATURES Location/Qualifiers  
 BASE COUNT 12605 a 11725 c 11351 g 14317 t  
 ORIGIN  
 468 100 0.0  
 HS454M7 Human DNA sequence from clone RP3-454M7 on chromosome Xq25-26.3, complete sequence. 151152 bp, DNA, linear, PRI 05-JUN-2003  
 ACCESSION AL022162  
 VERSION AL022162.1 GI:3171881  
 KEYWORDS HTG.  
 SOURCE Homo sapiens (human)  
 ORGANISM Homo sapiens  
 Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.  
 REFERENCE 1 (bases 1 to 151152)  
 AUTHORS Pavitt, R.  
 TITLE Direct Submission  
 JOURNAL Submitted (05-JUN-2003) Wellcome Trust Sanger Institute, Hinxton, Cambridgeshire, CB10 1SA, UK. E-mail enquiries: humquery@sanger.ac.uk Clone requests: clonerequest@sanger.ac.uk  
 COMMENT On Jun 2, 1998 this sequence version replaced gi:2969945.  
 -----  
 Center: Wellcome Trust Sanger Institute  
 Center code: SC  
 Web site: <http://www.sanger.ac.uk>  
 Contact: humquery@sanger.ac.uk

During sequence assembly data is compared from overlapping clones. Where differences are found these are annotated as variations together with a note of the overlapping clone name. Note that the variation annotation may not be found in the sequence submission corresponding to the overlapping clone, as we submit sequences with only a small overlap as described above.

This sequence was finished as follows unless otherwise noted: all regions were either double-stranded or sequenced with an alternate chemistry or covered by high quality data (i.e., phred quality  $\geq$  30); an attempt was made to resolve all sequencing problems, such as compressions and repeats; all regions were covered by at least one plasmid subclone or more than one M13 subclone; and the assembly was confirmed by restriction digest, except on the rare occasion of the clone being a YAC.

The following abbreviations are used to associate primary accession numbers given in the feature table with their source databases: Em:, EMBL; Sw:, SWISSPROT; Tr:, TREMBL; Wp:, WORMPEP; Information on the WORMPEP database can be found at [http://www.sanger.ac.uk/Projects/C\\_elegans/wormpep](http://www.sanger.ac.uk/Projects/C_elegans/wormpep) This sequence was generated from part of bacterial clone contigs of human chromosome X, constructed by the Sanger Centre Chromosome X Mapping Group. Further information can be found at <http://www.sanger.ac.uk/HGP/ChrX> RP3-454M7 is from the library RPCI-3 constructed by the group of

Pieter de Jong. For further details see  
<http://www.chori.org/bacpac/home.htm>  
 VECTOR: pCYPAC2  
 This sequence is the entire insert of clone RP3-454M7.

FEATURES	Location/Qualifiers
source	1..151152 /organism="Homo sapiens" /mol_type="genomic DNA" /db_xref="RZPD:RPCIP704M07454" /db_xref="taxon:9606" /chromosome="X" /map="q25-26.3" /clone="RP3-454M7" /clone_lib="RPCI-3"
gene	767..35998 /gene="OCRL1"
mRNA	join(<767..877,1303..1392,2075..2195,2282..2443, 3992..4093,4621..4735,5826..5942,6041..6228,9214..9325, 10696..10805,12706..12841,18582..18692,19339..19504, 19759..19994,30444..30560,31621..31705,32328..32455, 33287..33398,33588..35998) /gene="OCRL1" /product="dJ454M7.1.1 (Lowe Oculocerebrorenal Syndrome)" /note="variant 1 match: cDNAs: Em:M88162 Em:U57627 Em:M74161 Em:AF040094 match: ESTs: Em:AA368192 Em:AA704671 Em:AA515789 Em:AA102623 Em:AA126320 Em:T63686 Em:AA84344 Em:N92504 Em:AA044611 Em:AA188493 Em:AA743649 Em:AA836673 Em:R67320 Em:AA100629 Em:AA085500 Em:R94403 Em:AA056506 Em:AA034375 Em:AA142870 Em:AA150871 Em:T84251 Em:AA122020 Em:AA906612 Em:F07337 Em:AA628152 Em:AA878369 Em:AA640853 Em:AA189134 Em:AA044666 Em:AA740555 Em:R18793 Em:AA844284 Em:AA904845 Em:AA042798 Em:AA122019 Em:H53971 Em:W38961 Em:AA805220 Em:AA868822 Em:AA032176 Em:AA034374 Em:T84250 Em:N56932 Em:AA169401 Em:AA188849 Em:N46002 Em:AA056392 Em:H87857 Em:W52373 Em:AA587050 Em:AA100630 Em:T88888 Em:H27722 Em:AA186750 Em:R66483 Em:T28294" /evidence=not_experimental join(<769..877,1303..1392,2075..2195,2282..2443, 3992..4093,4621..4735,5826..5942,6041..6228,9214..9325, 10696..10805,12706..12841,18582..18692,19339..19504, 19759..19994,27786..27809,30444..30560,31621..31705, 32328..32455,33287..33398,33588..33712) /gene="OCRL1" /codon_start=1 /evidence=not_experimental /product="dJ454M7.1.2 (variant 2)" /protein_id="CAA18150.1" /db_xref="GI:3171882" join(<769..877,1303..1392,2075..2195,2282..2443, 3992..4093,4621..4735,5826..5942,6041..6228,9214..9325, 10696..10805,12706..12841,18582..18692,19339..19504, 19759..19994,30444..30560,31621..31705,32328..32455, 33287..33398,33588..33712) /gene="OCRL1" /note="variant 1" /codon_start=1
CDS	
CDS	

/evidence=not\_experimental  
/product="dJ454M7.1.1 (Lowe Oculocerebrorenal Syndrome)"  
/protein\_id="CAA18151.1"  
/db\_xref="GI:4160528"  
repeat\_region 1586..1847  
/note="MIR repeat: matches 2..262 of consensus"  
repeat\_region 2642..2940  
/note="AluJb repeat: matches 1..302 of consensus"  
repeat\_region 6639..6933  
/note="MER33 repeat: matches 1..323 of consensus"  
repeat\_region 7178..8315  
/note="L1PA2 repeat: matches 5000..6146 of consensus"  
repeat\_region 11225..11294  
/note="MER5B repeat: matches 109..178 of consensus"  
repeat\_region 11345..11657  
/note="AluYb8 repeat: matches 1..310 of consensus"  
repeat\_region 11736..11797  
/note="31 copies 2 mer tt 72% conserved"  
repeat\_region 12436..12562  
/note="L2 repeat: matches 2579..2710 of consensus"  
repeat\_region 13276..13457  
/note="AluSg/x repeat: matches 129..310 of consensus"  
repeat\_region 13679..13873  
/note="MIR repeat: matches 5..213 of consensus"  
repeat\_region 14132..14206  
/note="MIR repeat: matches 163..233 of consensus"  
repeat\_region 14207..14413  
/note="MER8 repeat: matches 2..239 of consensus"  
repeat\_region 14414..14548  
/note="MIR repeat: matches 12..163 of consensus"  
repeat\_region 14793..15073  
/note="AluY repeat: matches 1..311 of consensus"  
repeat\_region 15383..15589  
/note="MER3 repeat: matches 1..209 of consensus"  
repeat\_region 16139..16279  
/note="MER5B repeat: matches 29..178 of consensus"  
repeat\_region 16317..16466  
/note="MIR repeat: matches 52..212 of consensus"  
repeat\_region 16667..17000  
/note="L1PA9 repeat: matches 5829..6163 of consensus"  
repeat\_region 17001..17301  
/note="AluYb8 repeat: matches 1..302 of consensus"  
repeat\_region 17302..17642  
/note="L1PA9 repeat: matches 5491..5829 of consensus"  
repeat\_region 18285..18620  
/note="2 copies 168 mer 78% conserved"  
repeat\_region 18772..18981  
/note="MIR repeat: matches 6..242 of consensus"  
repeat\_region 18945..19005  
/note="L2 repeat: matches 2648..2702 of consensus"  
repeat\_region 20349..20489  
/note="MIR repeat: matches 1..150 of consensus"  
repeat\_region 20543..20697  
/note="MER5A repeat: matches 22..188 of consensus"  
repeat\_region 21496..21830  
/note="L1MC4 repeat: matches 7477..7849 of consensus"  
repeat\_region 22420..22650

repeat\_region /note="MER46A repeat: matches 1..236 of consensus"  
repeat\_region 22894..22965  
repeat\_region /note="3 copies 24 mer 83% conserved"  
repeat\_region 24309..24606  
repeat\_region /note="AluSx repeat: matches 1..299 of consensus"  
repeat\_region 25081..25134  
repeat\_region /note="27 copies 2 mer ta 70% conserved"  
repeat\_region 25168..25193  
repeat\_region /note="13 copies 2 mer tg 100% conserved"  
repeat\_region 25262..25301  
repeat\_region /note="20 copies 2 mer tc 90% conserved"  
repeat\_region 25302..25642  
repeat\_region /note="L2 repeat: matches 2078..2419 of consensus"  
repeat\_region 26542..26704  
repeat\_region /note="MIR repeat: matches 1..160 of consensus"  
repeat\_region 26822..27057  
repeat\_region /note="MIR repeat: matches 8..255 of consensus"  
repeat\_region 28330..28399  
repeat\_region /note="MIR repeat: matches 82..151 of consensus"  
repeat\_region 30715..30819  
repeat\_region /note="MIR repeat: matches 35..138 of consensus"  
repeat\_region 31196..31319  
repeat\_region /note="AluJb repeat: matches 2..125 of consensus"  
repeat\_region 37202..37675  
repeat\_region /note="L2 repeat: matches 1597..2041 of consensus"  
repeat\_region 37676..37990  
repeat\_region /note="AluJb repeat: matches 1..312 of consensus"  
repeat\_region 37991..38142  
repeat\_region /note="L2 repeat: matches 2041..2182 of consensus"  
repeat\_region 38143..38316  
repeat\_region /note="MER5A repeat: matches 3..189 of consensus"  
repeat\_region 38317..38464  
repeat\_region /note="L2 repeat: matches 2182..2419 of consensus"  
repeat\_region 38676..38801  
repeat\_region /note="MIR repeat: matches 11..134 of consensus"  
repeat\_region 38858..38984  
repeat\_region /note="MIR repeat: matches 123..257 of consensus"  
repeat\_region 39284..39886  
repeat\_region /note="L2 repeat: matches 2147..2748 of consensus"  
repeat\_region 39913..40014  
repeat\_region /note="MIR repeat: matches 175..262 of consensus"  
repeat\_region 40015..40311  
repeat\_region /note="AluSg repeat: matches 1..297 of consensus"  
repeat\_region 40312..40428  
repeat\_region /note="MIR repeat: matches 14..175 of consensus"  
repeat\_region 40667..40774  
repeat\_region /note="L2 repeat: matches 2616..2702 of consensus"  
repeat\_region 40776..41088  
repeat\_region /note="AluSx repeat: matches 1..305 of consensus"  
repeat\_region 41528..41936  
repeat\_region /note="L2 repeat: matches 2267..2709 of consensus"  
repeat\_region 42180..42713  
repeat\_region /note="L1MB3 repeat: matches 5584..6153 of consensus"  
repeat\_region 42714..43014  
repeat\_region /note="AluJb repeat: matches 1..312 of consensus"  
repeat\_region 43015..43042  
repeat\_region /note="L1MB3 repeat: matches 6153..6178 of consensus"

```
repeat_region 43197..43238
repeat_region 43282..43574
repeat_region 45284..45741
repeat_region 45835..45905
repeat_region 45906..46207
repeat_region 46208..46584
repeat_region 46714..47015
repeat_region 47016..47159
repeat_region 47168..47374
repeat_region 47427..47581
repeat_region 47611..47774
repeat_region 48682..48987
repeat_region 49541..49678
repeat_region 49698..49898
repeat_region 49909..49978
repeat_region 50220..50423
repeat_region 50421..50492
repeat_region 50846..50915
repeat_region 50914..51068
repeat_region 51124..51292
repeat_region 51517..51587
repeat_region 52716..52853
repeat_region 52994..53224
repeat_region 54036..54154
repeat_region 54234..54586
repeat_region 54612..54704
repeat_region 54708..54755
repeat_region 55103..55409
repeat_region 55876..56326
```

```
/note="L2 repeat: matches 2225..2658 of consensus"
repeat_region      56404..56697
/repeat_region      56760..56882
/note="L2 repeat: matches 2605..2730 of consensus"
repeat_region      57036..57226
/note="MIR repeat: matches 73..262 of consensus"
repeat_region      57448..57579
/note="L1PA16 repeat: matches 6025..6157 of consensus"
repeat_region      57817..58128
/note="L2 repeat: matches 2434..2746 of consensus"
repeat_region      58772..59030
/note="MIR repeat: matches 1..262 of consensus"
repeat_region      59040..59091
/note="MIR repeat: matches 206..257 of consensus"
repeat_region      59050..59118
/note="L2 repeat: matches 2626..2729 of consensus"
repeat_region      59465..59797
/note="AluSx repeat: matches 1..301 of consensus"
repeat_region      61554..61833
/note="AluSx repeat: matches 6..286 of consensus"
repeat_region      62011..62239
/note="MIR repeat: matches 2..242 of consensus"
repeat_region      62265..62379
/note="L2 repeat: matches 2430..2545 of consensus"
repeat_region      63472..63529
/note="MIR repeat: matches 185..242 of consensus"
repeat_region      64262..64313
/note="MIR repeat: matches 92..143 of consensus"
repeat_region      64330..64409
/note="MER33 repeat: matches 241..324 of consensus"
repeat_region      64459..64631
/note="L1MA10 repeat: matches 5999..6322 of consensus"
repeat_region      64637..64862
/note="MER33 repeat: matches 5..225 of consensus"
repeat_region      65788..66082
/note="AluJo repeat: matches 6..304 of consensus"
repeat_region      66968..66991
/note="L2 repeat: matches 2470..2493 of consensus"
repeat_region      67036..67653
/note="L2 repeat: matches 1882..2511 of consensus"
repeat_region      67654..67700
/note="L1PA16 repeat: matches 4148..4193 of consensus"
repeat_region      67701..67998
/note="AluY repeat: matches 1..296 of consensus"
repeat_region      67999..68463
/note="L1PA16 repeat: matches 4193..4655 of consensus"
repeat_region      68464..68826
/note="THE1B repeat: matches 1..364 of consensus"
repeat_region      68827..70335
/note="L1PA16 repeat: matches 4655..6143 of consensus"
repeat_region      70349..70538
/note="L2 repeat: matches 1697..1895 of consensus"
repeat_region      70565..70865
/note="AluY repeat: matches 1..305 of consensus"
repeat_region      70932..71126
/note="L1ME3 repeat: matches 5734..5939 of consensus"
```

repeat\_region 71385..71690  
/note="AluYa5 repeat: matches 1..310 of consensus"  
repeat\_region 71717..72253  
/note="MLT1F repeat: matches 11..513 of consensus"  
repeat\_region 72615..72631  
/note="MIR repeat: matches 196..212 of consensus"  
repeat\_region 72632..72870  
/note="MER8 repeat: matches 1..239 of consensus"  
repeat\_region 72871..73028  
/note="MIR repeat: matches 45..196 of consensus"  
repeat\_region 73892..73979  
/note="MIR repeat: matches 59..147 of consensus"  
repeat\_region 74431..74484  
/note="27 copies 2 mer ca 96% conserved"  
repeat\_region 74436..74483  
/note="2 copies 24 mer 100% conserved"  
repeat\_region 74504..74671  
/note="MIR repeat: matches 2..171 of consensus"  
repeat\_region 75019..75185  
/note="L2 repeat: matches 2517..2704 of consensus"  
repeat\_region 75149..75249  
/note="MIR repeat: matches 28..137 of consensus"  
repeat\_region 75397..75588  
/note="MLT1A1 repeat: matches 1..194 of consensus"  
repeat\_region 75646..75831  
/note="MLT1A1 repeat: matches 171..365 of consensus"  
repeat\_region 76554..76826  
/note="AluSg1 repeat: matches 1..308 of consensus"  
repeat\_region 76863..76903  
/note="L2 repeat: matches 2652..2693 of consensus"  
repeat\_region 77089..77189  
/note="MIR repeat: matches 41..144 of consensus"  
repeat\_region 77359..77679  
/note="AluSx repeat: matches 1..301 of consensus"  
repeat\_region 78584..78722  
/note="L2 repeat: matches 2615..2750 of consensus"  
repeat\_region 79058..79304  
/note="MIR repeat: matches 8..262 of consensus"  
repeat\_region 81458..81515  
/note="MIR repeat: matches 95..154 of consensus"  
repeat\_region 81526..81665  
/note="L2 repeat: matches 2352..2503 of consensus"  
repeat\_region 81793..81843  
/note="L2 repeat: matches 2706..2750 of consensus"  
repeat\_region 82019..82082  
/note="MIR repeat: matches 90..153 of consensus"  
repeat\_region 82664..82739  
/note="L2 repeat: matches 2647..2722 of consensus"  
repeat\_region 82740..83045  
/note="AluSx repeat: matches 1..312 of consensus"  
repeat\_region 83046..83071  
/note="L2 repeat: matches 2722..2747 of consensus"  
repeat\_region 83813..83946  
/note="MIR repeat: matches 89..250 of consensus"  
repeat\_region 83904..83954  
/note="L2 repeat: matches 2648..2698 of consensus"  
repeat\_region 83963..84024

repeat\_region /note="MIR repeat: matches 77..140 of consensus"  
84133..84258  
repeat\_region /note="MIR repeat: matches 7..136 of consensus"  
84602..84697  
repeat\_region /note="MIR repeat: matches 49..135 of consensus"  
85012..85350  
repeat\_region /note="MLT1A2 repeat: matches 1..340 of consensus"  
85365..85456  
repeat\_region /note="MIR repeat: matches 33..128 of consensus"  
85526..85776  
repeat\_region /note="MIR repeat: matches 7..262 of consensus"  
85935..86011  
repeat\_region /note="MER58A repeat: matches 42..121 of consensus"  
86101..86173  
repeat\_region /note="MER58A repeat: matches 143..219 of consensus"  
87299..87643  
repeat\_region /note="AluYb8 repeat: matches 1..310 of consensus"  
88003..88303  
repeat\_region /note="AluSx repeat: matches 1..301 of consensus"  
92655..92799  
repeat\_region /note="L1MC5 repeat: matches 7720..7866 of consensus"  
99017..99109  
repeat\_region /note="L2 repeat: matches 2388..2488 of consensus"  
99392..99521  
repeat\_region /note="L2 repeat: matches 2576..2710 of consensus"  
99694..99834  
repeat\_region /note="L2 repeat: matches 2610..2750 of consensus"  
100051..100090  
repeat\_region /note="20 copies 2 mer tt 80% conserved"  
100093..100400  
repeat\_region /note="AluSx repeat: matches 3..312 of consensus"  
100764..100931  
repeat\_region /note="MER3 repeat: matches 3..207 of consensus"  
101144..101446  
repeat\_region /note="AluJo repeat: matches 1..292 of consensus"  
101798..101867  
repeat\_region /note="L2 repeat: matches 2672..2744 of consensus"  
101952..102471  
repeat\_region /note="MER1A repeat: matches 6..527 of consensus"  
102850..103006  
repeat\_region /note="MIR repeat: matches 20..168 of consensus"  
103007..103052  
repeat\_region /note="MLT1A1 repeat: matches 1..51 of consensus"  
103053..103356  
repeat\_region /note="AluSp repeat: matches 1..303 of consensus"  
103357..103729  
repeat\_region /note="MLT1A1 repeat: matches 51..365 of consensus"  
103730..103791  
repeat\_region /note="MIR repeat: matches 168..231 of consensus"  
103886..103998  
repeat\_region /note="MSTA repeat: matches 1..114 of consensus"  
103996..104323  
repeat\_region /note="MSTA repeat: matches 1..388 of consensus"  
104372..104503  
repeat\_region /note="AluY repeat: matches 166..297 of consensus"  
104594..104824  
repeat\_region /note="MIR repeat: matches 10..259 of consensus"

```
repeat_region 104874..104954
repeat_region 105235..105332
repeat_region 107333..107459
repeat_region 107460..107589
repeat_region 107590..107718
repeat_region 107755..108017
repeat_region 108019..108208
repeat_region 108326..108922
repeat_region 109592..109635
repeat_region 110302..110511
repeat_region 110589..111071
repeat_region 111077..111135
repeat_region 111153..111414
repeat_region 111419..111617
repeat_region 111622..112876
repeat_region 112873..114198
repeat_region 114206..115694
repeat_region 115723..116219
repeat_region 116220..116291
repeat_region 116283..116348
repeat_region 116377..118409
repeat_region 118410..118683
repeat_region 118684..118923
repeat_region 118955..119117
repeat_region 119118..119284
repeat_region 119285..119682
repeat_region 119683..119810
repeat_region 119830..120493
repeat_region 120522..120894
```

```
/note="MLT1B repeat: matches 1..426 of consensus"
repeat_region 120923..121042
/note="5 copies 24 mer 68% conserved"
repeat_region 121180..121227
/note="2 copies 24 mer 95% conserved"
repeat_region 121184..121227
/note="22 copies 2 mer gt 100% conserved"
repeat_region 122617..122772
/note="MER5A repeat: matches 4..188 of consensus"
repeat_region 122787..122900
/note="MER5B repeat: matches 91..173 of consensus"
repeat_region 122901..123193
/note="AluJo repeat: matches 4..298 of consensus"
repeat_region 123194..123275
/note="MER5B repeat: matches 1..91 of consensus"
repeat_region 123437..124087
/note="L2 repeat: matches 1555..2750 of consensus"
repeat_region 124164..124586
/note="L2 repeat: matches 57..485 of consensus"
repeat_region 125405..125535
/note="Charlie4a repeat: matches 369..495 of consensus"
repeat_region 125536..125695
/note="FRAM repeat: matches 2..161 of consensus"
repeat_region 125696..126026
/note="Charlie4a repeat: matches 19..369 of consensus"
repeat_region 126098..126459
/note="MLT1A1 repeat: matches 1..365 of consensus"
repeat_region 126630..126693
/note="L2 repeat: matches 2641..2704 of consensus"
repeat_region 126784..127362
/note="L2 repeat: matches 2176..2750 of consensus"
repeat_region 127366..127489
/note="MIR repeat: matches 46..185 of consensus"
repeat_region 127679..127826
/note="L2 repeat: matches 2552..2691 of consensus"
repeat_region 127827..128126
/note="AluJo repeat: matches 4..302 of consensus"
repeat_region 128127..128405
/note="L2 repeat: matches 2241..2552 of consensus"
repeat_region 128518..128663
/note="L2 repeat: matches 1873..2021 of consensus"
repeat_region 128674..129015
/note="MLT1A1 repeat: matches 1..358 of consensus"
repeat_region 129016..129205
/note="L2 repeat: matches 1672..1868 of consensus"
repeat_region 129216..129297
/note="L2 repeat: matches 2639..2710 of consensus"
repeat_region 129340..129554
/note="MIR repeat: matches 53..260 of consensus"
repeat_region 129661..129924
/note="MIR repeat: matches 2..261 of consensus"
repeat_region 131041..131232
/note="AluSg/x repeat: matches 135..292 of consensus"
repeat_region 131267..131548
/note="AluY repeat: matches 18..311 of consensus"
repeat_region 131743..132226
/note="MLT1G repeat: matches 31..496 of consensus"
```

```
repeat_region 132996..133294
repeat_region 133642..133701
repeat_region 134184..134313
repeat_region 134373..134437
repeat_region 134438..134744
repeat_region 134748..134835
repeat_region 134878..135187
repeat_region 135493..135866
repeat_region 135888..136007
repeat_region 136270..136561
repeat_region 136598..136661
repeat_region 136902..137090
repeat_region 137099..137227
repeat_region 137228..137524
repeat_region 137525..137870
repeat_region 137893..138056
repeat_region 138057..138345
repeat_region 138346..138472
repeat_region 138474..138539
repeat_region 138554..138675
repeat_region 138694..139033
repeat_region 138993..139044
repeat_region 139737..139807
repeat_region 139808..139873
repeat_region 139874..140272
repeat_region 140332..140461
repeat_region 140611..140903
repeat_region 141410..141594
repeat_region 142664..142699
```

```

repeat_region /note="18 copies 2 mer tc 100% conserved"
repeat_region 142714..142995
repeat_region /note="AluSc repeat: matches 1..278 of consensus"
repeat_region 143097..143180
repeat_region /note="L2 repeat: matches 2643..2749 of consensus"
repeat_region 143339..143662
repeat_region /note="MLT1A1 repeat: matches 6..365 of consensus"
repeat_region 143783..143885
repeat_region /note="L2 repeat: matches 2593..2702 of consensus"
repeat_region 145806..145889
repeat_region /note="MIR repeat: matches 37..130 of consensus"
repeat_region 145957..146261
repeat_region /note="AluSq repeat: matches 1..308 of consensus"
repeat_region 146264..146376
repeat_region /note="MIR repeat: matches 117..235 of consensus"
repeat_region 147583..147657
repeat_region /note="L2 repeat: matches 2422..2502 of consensus"
repeat_region 147859..147978
repeat_region /note="L2 repeat: matches 2616..2750 of consensus"
repeat_region 148013..148084
repeat_region /note="L2 repeat: matches 2636..2707 of consensus"
repeat_region 148687..149141
repeat_region /note="LTR16B repeat: matches 1..461 of consensus"
repeat_region 150442..151102
repeat_region /note="L2 repeat: matches 1490..2109 of consensus"

```

## BASE COUNT

## ORIGIN

468 100 0.0

AF195953 Homo sapiens membrane-bound aminopeptidase P (XNPEP2) gene, complete cds. 206618 bp, DNA, linear, PRI 26-MAR-2002

ACCESSION AF195953

VERSION AF195953.2 GI:19718557

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1 (bases 1 to 206618)

AUTHORS Ryan, J.W., Jin, L., Horvath, I. and Sprinkle, T.J.C.

TITLE Human membrane-bound aminopeptidase P genomic DNA

JOURNAL Unpublished

REFERENCE 2 (bases 1 to 206618)

AUTHORS Ryan, J.W., Jin, L., Horvath, I. and Sprinkle, T.J.C.

TITLE Direct Submission

JOURNAL Submitted (18-OCT-1999) Vascular Biology Center, Medical College of Georgia, 1120 15th Street, Augusta, GA 30912, USA

REFERENCE 3 (bases 1 to 206618)

AUTHORS Ryan, J.W., Jin, L., Horvath, I. and Sprinkle, T.J.C.

TITLE Direct Submission

JOURNAL Submitted (26-MAR-2002) Vascular Biology Center, Medical College of Georgia, 1120 15th Street, Augusta, GA 30912, USA

REMARK Sequence update by submitter

COMMENT On Mar 26, 2002 this sequence version replaced gi:11066156.

FEATURES Location/Qualifiers

source 1..206618

/organism="Homo sapiens"

```

/mol_type="genomic DNA"
/db_xref="taxon:9606"
gene
  144189..176791
  /gene="XNPEP2"
mRNA
  join(144189..144502,147348..147421,149203..149313,
  150445..150508,151478..151582,151837..151923,
  152849..152995,155710..155811,156987..157068,
  157392..157587,158401..158490,159714..159823,
  160536..160613,161726..161797,164422..164482,
  165754..165823,166414..166518,167248..167307,
  167936..168012,172845..172934,173533..176791)
  /gene="XNPEP2"
  /product="membrane-bound aminopeptidase P"
5'UTR
  144189..144453
  /gene="XNPEP2"
CDS
  join(144454..144502,147348..147421,149203..149313,
  150445..150508,151478..151582,151837..151923,
  152849..152995,155710..155811,156987..157068,
  157392..157587,158401..158490,159714..159823,
  160536..160613,161726..161797,164422..164482,
  165754..165823,166414..166518,167248..167307,
  167936..168012,172845..172934,173533..173727)
  /gene="XNPEP2"
  /codon_start=1
  /product="membrane-bound aminopeptidase P"
  /protein_id="AAG28480.1"
  /db_xref="GI:11066157"
misc_feature
  160606..160608
  /gene="XNPEP2"
  /note="putative proton shuttle; unclassified site"
  161778..161780
  /gene="XNPEP2"
  /note="divalent metal ligand; metal-binding site"
  164435..164437
  /gene="XNPEP2"
  /note="divalent metal ligand; metal-binding site"
  166473..166475
  /gene="XNPEP2"
  /note="divalent metal ligand; metal-binding site"
  join(167307,167936..167937)
  /gene="XNPEP2"
  /note="divalent metal ligand; metal-binding site"
  167977..167979
  /gene="XNPEP2"
  /note="divalent metal ligand; metal-binding site"
  175728..176791
  /gene="XNPEP2"
3'UTR
  175728..176791
  /gene="XNPEP2"

```

BASE COUNT

ORIGIN

467 99 0.0

P\_AAH14799 Human cDNA sequence SEQ ID NO:12589. 243 bp, cDNA, PAT 26-JUN-2001  
ACCESSION P\_AAH14799KEYWORDS GENESEQ; Human; primer; detection; diagnosis; antisense therapy;  
gene therapy; patent; patentdb (v200414, 01-JUL-2004).

SOURCE Homo sapiens.

ORGANISM Homo sapiens.

REFERENCE 1 (bases 1 to 2243)  
 AUTHORS Ota,T., Isogai,T., Nishikawa,T., Hayashi,K., Saito,K.,  
 Yamamoto,J. Ishii,S., Sugiyama,T., Wakamatsu,A., Nagai,K.,  
 Otsuki,T.  
 TITLE Primer sets for synthesizing polynucleotides, particularly the 5602  
 full-length cDNAs defined in the specification, and for the  
 detection and/or diagnosis of the abnormality of the proteins  
 encoded by the full-length cDNAs.  
 JOURNAL Patent: EP1074617-A2; Filing Date: 28-JUL-2000; 2000EP-00116126;  
 Publication Date: 07-FEB-2001; Priority: 29-JUL-1999;  
 99JP-00248036. 27-AUG-1999; 99JP-00300253. 11-JAN-2000;  
 2000JP-00118776. 02-MAY-2000; 2000JP-00183767. 09-JUN-2000;  
 2000JP-00241899; Assignee: (HELI-) HELIX RES INST; Cross Reference:  
 WPI; 2001-318749/34; Patent Format: Claim 8; SEQ ID NO 12589; 2537pp  
 + Sequence Listing; English.  
 COMMENT The present invention describes primer sets for synthesising 5602  
 full-length cDNAs defined in the specification. Where a primer set  
 comprises: (a) an oligo-dT primer and an oligonucleotide  
 complementary to the complementary strand of a polynucleotide which  
 comprises one of the 5602 nucleotide sequences defined in the  
 specification, where the oligonucleotide comprises at least 15  
 nucleotides; or (b) a combination of an oligonucleotide comprising  
 a sequence complementary to the complementary strand of a  
 polynucleotide which comprises a 5'-end sequence and an  
 oligonucleotide comprising a sequence complementary to a  
 polynucleotide which comprises a 3'-end sequence, where the  
 oligonucleotide comprises at least 15 nucleotides and the  
 combination of the 5'-end sequence/3'-end sequence is selected from  
 those defined in the specification. The primer sets can be used in  
 antisense therapy and in gene therapy. The primers are useful for  
 synthesising polynucleotides, particularly full-length cDNAs. The  
 primers are also useful for the detection and/or diagnosis of the  
 abnormality of the proteins encoded by the full-length cDNAs. The  
 primers allow obtaining of the full-length cDNAs easily without any  
 specialised methods. AAH03166 to AAH13628 and AAH13633 to AAH18742  
 represent human cDNA sequences; AAB92446 to AAB95893 represent human  
 amino acid sequences; and AAH13629 to AAH13632 represent  
 oligonucleotides, all of which are used in the exemplification of  
 the present invention

FEATURES	Location/Qualifiers
BASE COUNT	467 a 630 c 637 g 509 t
ORIGIN	
467 99 0.0	
AK001855	Homo sapiens cDNA FLJ10993 fis, clone PLACE1002140. 2243 bp, mRNA, linear, PRI 30-JAN-2004
ACCESSION	AK001855
VERSION	AK001855.1 GI:7023382
KEYWORDS	oligo capping; fis (full insert sequence).
SOURCE	Homo sapiens (human)
ORGANISM	Homo sapiens Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
REFERENCE	1
AUTHORS	Ota,T., Suzuki,Y., Nishikawa,T., Otsuki,T., Sugiyama,T., Irie,R., Wakamatsu,A., Hayashi,K., Sato,H., Nagai,K., Kimura,K., Makita,H., Sekine,M., Obayashi,M., Nishi,T., Shibahara,T., Tanaka,T.,

Ishii,S., Yamamoto,J., Saito,K., Kawai,Y., Isono,Y., Nakamura,Y., Nagahari,K., Murakami,K., Yasuda,T., Iwayanagi,T., Wagatsuma,M., Shiratori,A., Sudo,H., Hosoiri,T., Kaku,Y., Kodaira,H., Kondo,H., Sugawara,M., Takahashi,M., Kanda,K., Yokoi,T., Furuya,T., Kikkawa,E., Omura,Y., Abe,K., Kamihara,K., Katsuta,N., Sato,K., Tanikawa,M., Yamazaki,M., Ninomiya,K., Ishibashi,T., Yamashita,H., Murakawa,K., Fujimori,K., Tanai,H., Kimata,M., Watanabe,M., Hiraoka,S., Chiba,Y., Ishida,S., Ono,Y., Takiguchi,S., Watanabe,S., Yosida,M., Hotuta,T., Kusano,J., Kanehori,K., Takahashi-Fujii,A., Hara,H., Tanase,T., Nomura,Y., Togiya,S., Komai,F., Hara,R., Takeuchi,K., Arita,M., Imose,N., Musashino,K., Yuuki,H., Oshima,A., Sasaki,N., Aotsuka,S., Yoshikawa,Y., Matsunawa,H., Ichihara,T., Shiohata,N., Sano,S., Moriya,S., Momiyama,H., Satoh,N., Takami,S., Terashima,Y., Suzuki,O., Nakagawa,S., Senoh,A., Mizoguchi,H., Goto,Y., Shimizu,F., Wakebe,H., Hishigaki,H., Watanabe,T., Sugiyama,A., Takemoto,M., Kawakami,B., Yamazaki,M., Watanabe,K., Kumagai,A., Itakura,S., Fukuzumi,Y., Fujimori,Y., Komiyama,M., Tashiro,H., Tanigami,A., Fujiwara,T., Ono,T., Yamada,K., Fujii,Y., Ozaki,K., Hirao,M., Ohmori,Y., Kawabata,A., Hikiji,T., Kobatake,N., Inagaki,H., Ikeda,Y., Okamoto,S., Okitani,R., Kawakami,T., Noguchi,S., Itoh,T., Shigeta,K., Senba,T., Matsumura,K., Nakajima,Y., Mizuno,T., Morinaga,M., Sasaki,M., Togashi,T., Oyama,M., Hata,H., Watanabe,M., Komatsu,T., Mizushima-Sugano,J., Satoh,T., Shirai,Y., Takahashi,Y., Nakagawa,K., Okumura,K., Nagase,T., Nomura,N., Kikuchi,H., Masuho,Y., Yamashita,R., Nakai,K., Yada,T., Nakamura,Y., Ohara,O., Isogai,T. and Sugano,S.

**TITLE** Complete sequencing and characterization of 21,243 full-length human cDNAs  
**JOURNAL** Nat. Genet. 36 (1), 40-45 (2004)  
**PUBMED** 14702039  
**REFERENCE** 2  
**AUTHORS** Isogai,T., Ota,T., Hayashi,K., Sugiyama,T., Otsuki,T., Suzuki,Y., Nishikawa,T., Nagai,K., Sugano,S., Takahashi-Fujii,A., Hara,H., Tanase,T., Nomura,Y., Togiya,S., Komai,F., Hara,R., Takeuchi,K., Arita,M., Nabekura,T., Ishii,S., Kawai,Y., Saito,K., Yamamoto,J., Wakamatsu,A., Nakamura,Y., Nagahari,K., Masuho,Y. and Oshima,A.  
**TITLE** NEDO human cDNA sequencing project  
**JOURNAL** Unpublished  
**REFERENCE** 3 (bases 1 to 2243)  
**AUTHORS** Isogai,T. and Otsuki,T.  
**TITLE** Direct Submission  
**JOURNAL** Submitted (16-FEB-2000) Takao Isogai, Helix Research Institute, Genomics Laboratory; 1532-3 Yana, Kisarazu, Chiba 292-0812, Japan (E-mail:genomics@hri.co.jp, Tel:81-438-52-3975, Fax:81-438-52-3986)  
**COMMENT** NEDO human cDNA sequencing project supported by Ministry of International Trade and Industry of Japan; cDNA full insert sequencing: Research Association for Biotechnology; cDNA library construction, 5'- & 3'-end one pass sequencing and clone selection: Helix Research Institute (supported by Japan Key Technology Center etc.) and Department of Virology, Institute of Medical Science, University of Tokyo.  
**FEATURES** Location/Qualifiers  
**source** 1..2243  
/organism="Homo sapiens"  
/mol\_type="mRNA"  
/db\_xref="taxon:9606"  
/clone="PLACE1002140"

CDS
   
 /tissue\_type="placenta"
   
 /clone\_lib="PLACE1"
   
 /note="cloning vector: pME18SFL3"
   
 6..374
   
 /note="unnamed protein product"
   
 /codon\_start=1
   
 /protein\_id="BAA91944.1"
   
 /db\_xref="GI:7023383"

BASE COUNT

ORIGIN

449 98 0.0

AX332625 Sequence 3134 from Patent WO0194629. 458 bp,

DNA, linear, PAT 09-JAN-2002

ACCESSION AX332625

VERSION AX332625.1 GI:18123259

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1

AUTHORS Young, P.E., Augustus, M., Carter, K.C., Ebner, R., Endress, G.,

Horrigan, S., Soppet, D.R. and Weaver, Z.

TITLE Cancer gene determination and therapeutic screening using signature

gene sets

JOURNAL Patent: WO 0194629-A 3134 13-DEC-2001;

Avalon Pharmaceuticals (US)

FEATURES Location/Qualifiers

source 1..458

/organism="Homo sapiens"

/mol\_type="unassigned DNA"

/db\_xref="taxon:9606"

BASE COUNT

ORIGIN

449 98 0.0

AX332852 Sequence 3361 from Patent WO0194629. 458 bp,

DNA, linear, PAT 09-JAN-2002

ACCESSION AX332852

VERSION AX332852.1 GI:18123486

KEYWORDS

SOURCE Homo sapiens (human)

ORGANISM Homo sapiens

Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;

Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.

REFERENCE 1

AUTHORS Young, P.E., Augustus, M., Carter, K.C., Ebner, R., Endress, G.,

Horrigan, S., Soppet, D.R. and Weaver, Z.

TITLE Cancer gene determination and therapeutic screening using signature

gene sets

JOURNAL Patent: WO 0194629-A 3361 13-DEC-2001;

Avalon Pharmaceuticals (US)

FEATURES Location/Qualifiers

source 1..458

/organism="Homo sapiens"

/mol\_type="unassigned DNA"

/db\_xref="taxon:9606"

BASE COUNT  
ORIGIN

Dayhoff Protein Database (Rel 78, Mar 2004)

P\_AAB87540 Human PRO831 - Homo sapiens.

Length: 73 aa

Accession: P\_AAB87540;

Species: Homo sapiens.

Keywords: Human; PRO protein; mapping; patent; GENESEQ patentdb.

Patent number: WO200116318-A2.

Publication date: 08-MAR-2001.

Filing date: 24-AUG-2000; 2000WO-US023328.

Priority: 01-SEP-1999; 99WO-US020111. 15-SEP-1999; 99WO-US021090.

07-DEC-1999; 99US-0169495P. 09-DEC-1999; 99US-0170262P.

11-JAN-2000; 2000US-0175481P. 18-FEB-2000; 2000WO-US004341.

18-FEB-2000; 2000WO-US004342. 22-FEB-2000; 2000WO-US004414.

01-MAR-2000; 2000WO-US005601. 03-MAR-2000; 2000US-0187202P.

21-MAR-2000; 2000US-0191007P. 30-MAR-2000; 2000WO-US008439.

25-APR-2000; 2000US-0199397P. 22-MAY-2000; 2000WO-US014042.

05-JUN-2000; 2000US-0209832P.

Assignee: (GETH) GENENTECH INC.

Inventors: Eaton DL, Filvaroff E, Gerritsen ME, Goddard A, Godowski PJ;

Grimaldi CJ, Gurney AL, Watanabe CK, Wood WI;

Cross reference: WPI; 2001-183260/18. N-PSDB; AAF92072.

Title: Eighty four nucleic acids encoding PRO polypeptides, useful in molecular biology, including use as hybridization probes, and in chromosome and gene mapping.

Patent format: Claim 12; Fig 30; 278pp; English.

Comment: The present sequence is a human PRO polypeptide (secreted and transmembrane). The PRO protein, and PRO agonists, PRO antagonists or anti-PRO antibodies are useful for preparation of a medicament useful in the treatment of a condition which is responsive to the PRO protein, agonists, antagonists or anti-PRO antibodies. The PRO protein may also be employed as molecular weight markers for protein electrophoresis. The PRO coding sequence has applications in molecular biology, including use as hybridisation probes, and in chromosome and gene mapping

Database: GENESEQ patent database (v200414, 01-JUL-2004).

P\_AAY99346 Human PRO831 (UNQ471) amino acid sequence SEQ ID NO:22 - Homo sapiens.

Length: 73 aa

Accession: P\_AAY99346;

Species: Homo sapiens.

Keywords: Human; PRO polypeptide; membrane bound protein; receptor; diagnosis; transmembrane; secretion; immunoadhesion; pharmaceutical; screening; patent; GENESEQ patentdb.

Patent number: WO200012708-A2.

Publication date: 09-MAR-2000.

Filing date: 01-SEP-1999; 99WO-US020111.

Priority: 01-SEP-1998; 98US-0098716P. 01-SEP-1998; 98US-0098749P.

01-SEP-1998; 98US-0098750P. 18-NOV-1998; 98US-0108858P. 18-NOV-1998;

98US-0108904P. plus 119 more dates.

Assignee: (GETH) GENENTECH INC.

Inventors: Baker K, Goddard A, Gurney AL, Smith V, Watanabe CK, Wood WI;

Cross reference: WPI; 2000-237871/20. N-PSDB; AAA37028.

Title: New mammalian DNA sequences encoding transmembrane, receptor or secreted PRO polypeptides, useful for screening of potential peptide or small molecule inhibitors of the relevant

receptor/ligand interactions.

Patent format: Claim 12; Fig 14; 773pp; English.

Comment: AAA37022 to AAA37144 encode the new isolated human transmembrane, receptor or secreted PRO polypeptides given in AAY99340 to AAY99462. The transmembrane and receptor PRO proteins can be used for screening of potential peptide or small molecule inhibitors of the relevant receptor/ligand interactions. The polypeptides and nucleotide sequences encoding them have various industrial applications, including uses as pharmaceutical and diagnostic agents. AAA37145 to AAA37330 represent PCR primers and hybridisation probes used in the isolation of the PRO polypeptides from the present invention

Database: GENESEQ patent database (v200414, 01-JUL-2004).